13th Apr 2016 11:27
LONDON (Alliance News) - Premaitha Health PLC Wednesday said three of its major shareholders sold their entire stakes to "meet demand from institutions and from a director" on Tuesday.
Zoragen Biotechnologies LLP, Loxbridge Research LLP and Rupert Lywood disposed of 29.4 million, 9.3 million and 2.1 million shares respectively.
The 40.8 million shares were placed by the group's joint broker finnCap. The issued share capital remains unchanged at 228.2 million shares of 10 pence each, the company said.
Premaitha, which develops non-invasive prenatal screening tests for pregnant women, also said Non-Executive Director Adam Reynolds acquired 380,000 shares in the placing at a price of 6.5 pence per share. As a result, Reynolds' shareholding has increased to 3.7 million shares, representing 1.61% of the issued share capital.
The stock was up 1.4% at 9.00p Wednesday.
By Arvind Bhunjun; [email protected]; @ArvindBhunjun
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Premaitha Health